Want to see SE:CEVI full AI Analyst Report?
CEVI Stock Chart & Stats
kr161.00
-kr3.60(-2.10%)
At close: 4:00 PM EST
kr161.00
-kr3.60(-2.10%)
Day’s Range― - ―
52-Week Rangekr117.60 - kr192.20
Previous CloseN/A
Volume5.79K
Average Volume (3M)36.08K
Market Cap
kr3.41B
Enterprise Valuekr3.16B
Total Cash (Recent Filing)kr230.22M
Total Debt (Recent Filing)kr22.43M
Price to Earnings (P/E)25.4
Beta0.81
Next Earnings
Jul 17, 2026EPS Estimate
1.41Next Dividend Ex-DateN/A
Dividend Yield1.61%
Share Statistics
EPS (TTM)5.62
Shares Outstanding23,851,547
10 Day Avg. Volume30,505
30 Day Avg. Volume36,083
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)6.36
Revenue Forecast (FY)kr781.40M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a large equity base give the company durable financial flexibility to fund R&D, support distribution partners, and withstand cyclical downturns. This structural strength reduces refinancing risk and preserves optionality for strategic investment over 2–6 months and beyond.
High And Durable MarginsSustained high gross and net margins indicate structural pricing power and efficient cost structure in lab automation. Durable margins support reinvestment in product development and long-term profitability even if top-line growth softens, underpinning steady earnings power.
Operating Cash Generation Exceeds Net IncomeOperating cash flow materially outpacing accounting profits signals real cash generation from core operations, enabling funding of maintenance capex, service contracts and incremental working capital without heavy new financing. That supports sustainable operations and strategic investments.
Bears Say
Recent Revenue SlowdownA measurable decline in trailing revenue suggests market headwinds or softer instrument orders. Over a multi-month horizon this can limit recurring software/service expansion, slow installed-base driven revenue, and make sustained investment in growth initiatives harder without eroding margins or market share.
Weakened Free Cash Flow ConversionA sharp fall in FCF conversion implies higher capex, working-capital drain, or lower collection efficiency. Structurally, volatile FCF reduces the firm's ability to consistently fund dividends, buybacks or M&A, and increases sensitivity to operational shocks over the medium term.
Reliance On Instrument Sales (cyclical)A business mix still heavily dependent on upfront instrument sales creates inherent revenue cyclicality and longer sales cycles. Unless recurring software/service revenue meaningfully scales, growth and cash flow remain tied to capital spending cycles of hospitals and labs, increasing revenue volatility.
CellaVision AB News
CEVI FAQ
What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest stock price was kr117.60 and its highest was kr192.20 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is kr3.41B.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s upcoming earnings report date is Jul 17, 2026 which is in 12 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Apr 24, 2026. The company reported kr0.92 earnings per share for the quarter, missing the consensus estimate of kr1.544 by -kr0.624.
Is CellaVision AB overvalued?
According to Wall Street analysts CellaVision AB’s price is currently Overvalued.
Does CellaVision AB pay dividends?
CellaVision AB pays a Annually dividend of kr2.75 which represents an annual dividend yield of 1.61%. See more information on CellaVision AB dividends here
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 1.41.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of kr0.92 in its last earnings report, missing expectations of kr1.544. Following the earnings report the stock price went down -21.541%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in SE:CEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellaVision AB
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
CEVI Company Deck
CEVI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a broadly positive operational and financial picture: solid revenue and organic growth, a strong EBITDA margin above target, record Americas performance, important strategic progress (bone marrow CE Mark, software validation, DI-60 throughput improvements), a healthy cash position and a proposed dividend increase. Offsetting factors include a weak APAC quarter driven by comparables and tender timing, softness in reagents/software mix that pressured Q4 gross margin, FX headwinds, and near-term uncertainty on revenue ramp from new product launches (bone marrow and U.S. methanol-free reagents). Overall these negatives appear manageable against the company’s clear commercial momentum and strategic milestones.View all SE:CEVI earnings summariesTechnical Analysis
BICO Group AB Class B
―
Senzime AB
―
Xvivo Perfusion AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Options Prices
Currently, No data available
---